HC Wainwright Issues Pessimistic Forecast for Repare Therapeutics (NASDAQ:RPTX) Stock Price

Repare Therapeutics (NASDAQ:RPTX) had its target price decreased by analysts at HC Wainwright from $10.00 to $5.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 321.94% from the company’s previous close.

RPTX has been the topic of a number of other reports. Stifel Nicolaus reduced their price objective on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Bloom Burton lowered shares of Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 10th. Finally, Lifesci Capital restated a “market perform” rating on shares of Repare Therapeutics in a report on Friday, December 13th.

Repare Therapeutics Stock Down 0.4 %

Repare Therapeutics stock opened at $1.19 on Friday. The firm has a market cap of $50.38 million, a PE ratio of -0.59 and a beta of 0.87. Repare Therapeutics has a 52-week low of $1.06 and a 52-week high of $6.08. The company’s 50 day moving average is $1.25 and its two-hundred day moving average is $2.42.

Repare Therapeutics (NASDAQ:RPTX) last released its earnings results on Monday, March 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.10. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 40.87%. On average, equities research analysts anticipate that Repare Therapeutics will post -2.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Stifel Financial Corp grew its position in shares of Repare Therapeutics by 36.4% in the 3rd quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock valued at $178,000 after buying an additional 13,800 shares during the last quarter. Barclays PLC grew its position in Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company’s stock worth $29,000 after purchasing an additional 7,800 shares during the last quarter. Vontobel Holding Ltd. grew its position in Repare Therapeutics by 45.8% during the 4th quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company’s stock worth $46,000 after purchasing an additional 11,000 shares during the last quarter. Millennium Management LLC grew its position in Repare Therapeutics by 65.5% during the 4th quarter. Millennium Management LLC now owns 170,959 shares of the company’s stock worth $224,000 after purchasing an additional 67,638 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Repare Therapeutics by 204.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company’s stock worth $45,000 after purchasing an additional 23,127 shares during the last quarter. 85.09% of the stock is owned by hedge funds and other institutional investors.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.